{"pmid":32404473,"title":"Towards effective diagnostic assays for COVID-19: a review.","text":["Towards effective diagnostic assays for COVID-19: a review.","Countries globally are affected by the COVID-19 pandemic, with nearly two million cases and 120 000 deaths occurring within 4 months of the discovery of the severe acute respiratory syndrome coronavirus-2 in December 2019 in China. Accurate diagnoses of cases is key in managing the pandemic by identification, isolation and treatment of patients and defining the epidemiology of the virus. By mid-January 2020, a scientist from China published the full genome of the virus, which facilitated the development of accurate molecular diagnostic assays. By the end of January 2020, the WHO, in collaboration with laboratories in Asia, Europe and the USA, published several real-time reverse transcriptase PCR (rtRT-PCR) protocols that allowed identification of cases and development of commercial assays. Clinical investigations facilitated development of accurate case definition and guidance for laboratories on the optimum specimens and procedures for diagnoses. Currently, laboratory-based rtRT-PCR is the recommended test for diagnoses of acute cases to ensure patients can be identified and isolated and to facilitate the public health response. However, due to delays in diagnoses, severe shortage of tests and laboratory capacity, point-of-care molecular or antigen tests are becoming more attractive. Although serological tests are not suitable for diagnoses of acute cases, they are important to define epidemiological questions, including attack rate in the population, and to identify immune individuals. This review aimed to summarise the current available information for diagnoses of cases and to aid laboratories and healthcare workers to select the best assays and procedures.","J Clin Pathol","Venter, Marietjie","Richter, Karin","32404473"],"abstract":["Countries globally are affected by the COVID-19 pandemic, with nearly two million cases and 120 000 deaths occurring within 4 months of the discovery of the severe acute respiratory syndrome coronavirus-2 in December 2019 in China. Accurate diagnoses of cases is key in managing the pandemic by identification, isolation and treatment of patients and defining the epidemiology of the virus. By mid-January 2020, a scientist from China published the full genome of the virus, which facilitated the development of accurate molecular diagnostic assays. By the end of January 2020, the WHO, in collaboration with laboratories in Asia, Europe and the USA, published several real-time reverse transcriptase PCR (rtRT-PCR) protocols that allowed identification of cases and development of commercial assays. Clinical investigations facilitated development of accurate case definition and guidance for laboratories on the optimum specimens and procedures for diagnoses. Currently, laboratory-based rtRT-PCR is the recommended test for diagnoses of acute cases to ensure patients can be identified and isolated and to facilitate the public health response. However, due to delays in diagnoses, severe shortage of tests and laboratory capacity, point-of-care molecular or antigen tests are becoming more attractive. Although serological tests are not suitable for diagnoses of acute cases, they are important to define epidemiological questions, including attack rate in the population, and to identify immune individuals. This review aimed to summarise the current available information for diagnoses of cases and to aid laboratories and healthcare workers to select the best assays and procedures."],"journal":"J Clin Pathol","authors":["Venter, Marietjie","Richter, Karin"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32404473","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1136/jclinpath-2020-206685","keywords":["point-of-care testing","polymerase chain reaction","serology","virology"],"locations":["China","China","USA"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1666802845347741697,"score":9.490897,"similar":[{"pmid":32466458,"title":"Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","text":["Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19.","Viruses","Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K","32466458"],"abstract":["The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, accurate, and rapid diagnostic technologies to contain emerging and re-emerging pandemics. Real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) based assays performed on respiratory specimens remain the gold standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging with high sensitivity and specificity as well. Even though excellent techniques are available for the diagnosis of symptomatic patients with COVID-19 in well-equipped laboratories; critical gaps still remain in screening asymptomatic people who are in the incubation phase of the virus, as well as in the accurate determination of live viral shedding during convalescence to inform decisions for ending isolation. This review article aims to discuss the currently available laboratory methods and surveillance technologies available for the detection of COVID-19, their performance characteristics and highlight the gaps in current diagnostic capacity, and finally, propose potential solutions. We also summarize the specifications of the majority of the available commercial kits (PCR, EIA, and POC) for laboratory diagnosis of COVID-19."],"journal":"Viruses","authors":["Younes, Nadin","Al-Sadeq, Duaa W","Al-Jighefee, Hadeel","Younes, Salma","Al-Jamal, Ola","Daas, Hanin I","Yassine, Hadi M","Nasrallah, Gheyath K"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32466458","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/v12060582","keywords":["covid-19","sars-cov-2","diagnostic challenges","molecular testing","serology","viruses"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1668420887292936193,"score":310.99945},{"pmid":32416600,"title":"Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","text":["Comparison of seven commercial RT-PCR diagnostic kits for COVID-19.","The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories.","J Clin Virol","van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam","32416600"],"abstract":["The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been independently assessed. The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm AG, and Seegene). We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection (LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity. PCR efficiency was >/=96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene. We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in patients by experienced molecular diagnostic laboratories."],"journal":"J Clin Virol","authors":["van Kasteren, Puck B","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","de Jonge, Jorgen","van den Brandt, Annemarie","Molenkamp, Richard","Reusken, Chantal B E M","Meijer, Adam"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416600","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.jcv.2020.104412","keywords":["covid-19","coronavirus","in vitro diagnostics","rt-pcr","sars-cov-2","ncov-2019"],"topics":["Diagnosis"],"weight":1,"_version_":1666991242700914688,"score":251.06111},{"pmid":32361285,"pmcid":"PMC7194987","title":"Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays.","text":["Comparing the analytical performance of three SARS-CoV-2 molecular diagnostic assays.","In December 2019, a novel coronavirus (SARS-CoV-2) was first isolated from Wuhan city, China and within three months, the global community was challenged with a devastating pandemic. The rapid spread of the virus challenged diagnostic laboratories to rapidly develop molecular diagnostic methods. As SARS CoV-2 assays became available for testing on existing molecular platforms, laboratories devoted unprecedented energy and resources into evaluating the analytical performance of the new tests and in some cases developed their own diagnostic assays under FDA-EUA guidance. This study compares the validation of three different molecular assays at the Johns Hopkins Molecular Virology laboratory: the RealStar(R) SARS-CoV-2 RT-PCR, ePlex(R) SARS-CoV-2, and the CDC COVID-19 RT-PCR tests. Overall, our studies indicate a comparable analytical performance of the three assays for the detection of SARS-CoV-2.","J Clin Virol","Uhteg, Katharine","Jarrett, Junko","Richards, Mahmia","Howard, Craig","Morehead, Elizabeth","Geahr, Melissa","Gluck, Linda","Hanlon, Ann","Ellis, Brandon","Kaur, Harsimar","Simner, Patricia","Carroll, Karen C","Mostafa, Heba H","32361285"],"abstract":["In December 2019, a novel coronavirus (SARS-CoV-2) was first isolated from Wuhan city, China and within three months, the global community was challenged with a devastating pandemic. The rapid spread of the virus challenged diagnostic laboratories to rapidly develop molecular diagnostic methods. As SARS CoV-2 assays became available for testing on existing molecular platforms, laboratories devoted unprecedented energy and resources into evaluating the analytical performance of the new tests and in some cases developed their own diagnostic assays under FDA-EUA guidance. This study compares the validation of three different molecular assays at the Johns Hopkins Molecular Virology laboratory: the RealStar(R) SARS-CoV-2 RT-PCR, ePlex(R) SARS-CoV-2, and the CDC COVID-19 RT-PCR tests. Overall, our studies indicate a comparable analytical performance of the three assays for the detection of SARS-CoV-2."],"journal":"J Clin Virol","authors":["Uhteg, Katharine","Jarrett, Junko","Richards, Mahmia","Howard, Craig","Morehead, Elizabeth","Geahr, Melissa","Gluck, Linda","Hanlon, Ann","Ellis, Brandon","Kaur, Harsimar","Simner, Patricia","Carroll, Karen C","Mostafa, Heba H"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32361285","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jcv.2020.104384","keywords":["covid-19","lod","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495479971841,"score":244.20744},{"pmid":32341143,"title":"Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","text":["Comparison of Four Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made.","J Clin Microbiol","Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J","32341143"],"abstract":["Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the novel human coronavirus that causes coronavirus disease 2019 (COVID-19), was first discovered in December 2019 as the cause of an outbreak of pneumonia in the city of Wuhan, Hubei province, China. The clinical presentation of COVID-19 is fairly non-specific, and symptoms overlap with other seasonal respiratory infections concurrently circulating in the population. Furthermore, it is estimated that up to 80% of infected individuals experience mild symptoms or are asymptomatic, confounding efforts to reliably diagnose COVID-19 empirically. To support infection control measures, there is an urgent need for rapid and accurate molecular diagnostics to identify COVID-19 positive patients. In the present study, we have evaluated the analytical sensitivity and clinical performance of four SARS-CoV-2 molecular diagnostic assays granted Emergency Use Authorization by the FDA using nasopharyngeal swabs from symptomatic patients: the New York SARS-CoV-2 Real-time Reverse Transcriptase (RT)-PCR Diagnostic Panel (Modified CDC), the Simplexa COVID-19 Direct (Diasorin Molecular), GenMark ePlex SARS-CoV-2 assay (GenMark) and the Hologic Panther Fusion(R) SARS-CoV-2 assay (Hologic). This information is crucial for both laboratories and clinical teams, as decisions on which testing platform to implement are made."],"journal":"J Clin Microbiol","authors":["Zhen, Wei","Manji, Ryhana","Smith, Elizabeth","Berry, Gregory J"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32341143","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1128/JCM.00743-20","locations":["Wuhan","Hubei","China","New York"],"countries":["United States","China"],"countries_codes":["USA|United States","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495765184515,"score":243.1992},{"pmid":32245835,"title":"The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","text":["The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges.","The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak.","J Clin Microbiol","Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W","32245835"],"abstract":["The COVID-19 outbreak has had a major impact on clinical microbiology laboratories in the past several months. This commentary covers current issues and challenges for the laboratory diagnosis of infections caused by SARS-CoV-2. In the pre-analytical stage, collecting the proper respiratory tract specimen at the right time from the right anatomic site is essential for a prompt and accurate molecular diagnosis of COVID-19. Appropriate measures are required to keep laboratory staff safe while producing reliable test results. In the analytic stage, real-time RT-PCR assays remain the molecular test of choice for the etiologic diagnosis of SARS-CoV-2 infection while antibody-based techniques are being introduced as supplemental tools. In the postanalytical stage, testing results should be carefully interpreted using both molecular and serological findings. Finally, random access, integrated devices available at the point of care with scalable capacities will facilitate the rapid and accurate diagnosis and monitoring of SARS-CoV-2 infections and greatly assist in the control of this outbreak."],"journal":"J Clin Microbiol","authors":["Tang, Yi-Wei","Schmitz, Jonathan E","Persing, David H","Stratton, Charles W"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245835","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1128/JCM.00512-20","topics":["Diagnosis"],"weight":1,"_version_":1666138492035399681,"score":238.18274}]}